Defence And Security Tenders

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Ustekinumab, Atc L04ac05 (Obo) for the Period August 1St, 2024 - July 31St, 2025 (Plus Extension Option 1X12 Months)

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Bimatoprost + Timolol (Exclusively Edo), Atc S01ed62 (Obo) for the Period August 1St, 2024 - July 31St, 2026

Open House Drug Discount Agreements Ustekinumab, Atc L04ac05

Conducting Mining Activities 2020+ (Dns)

Medicines with the Active Ingredient Guselkumab (Atc: L04ac16)

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Pegvisomant, Atc H01ax01 (Obo) for the Period August 1St, 2024 - July 31St, 2026

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Fesoterodine, Atc G04bd11 (Obg) for the Period August 1St, 2024 - July 31St, 2026

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Omalizumab, Atc R03dx05 (Obo) for the Period August 1St, 2024 - July 31St, 2025 (Plus Extension Option 1X12 Months)

Work to Secure the Crete Du Marbre in the Forestry Sector of Beaurecueil (13)

Dps Insurance Services